153 related articles for article (PubMed ID: 37655165)
1. Evaluating Dual-Targeted ECO/siRNA Nanoparticles against an Oncogenic lncRNA for Triple Negative Breast Cancer Therapy with Magnetic Resonance Molecular Imaging.
Nicolescu C; Schilb A; Kim J; Sun D; Hall R; Gao S; Gilmore H; Schiemann WP; Lu ZR
Chem Biomed Imaging; 2023 Aug; 1(5):461-470. PubMed ID: 37655165
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the Efficacy of the Combination of RNAi of lncRNA DANCR with Chemotherapy to Treat Triple Negative Breast Cancer Using Magnetic Resonance Molecular Imaging.
Nicolescu C; Kim J; Sun D; Lu ZR
Bioconjug Chem; 2024 Mar; 35(3):381-388. PubMed ID: 38446033
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Targeted ECO/miR-200c Nanoparticles for Modulating Tumor Microenvironment and Treating Triple Negative Breast Cancer as Non-invasively Monitored by MR Molecular Imaging.
Schilb AL; Ayat NR; Vaidya AM; Hertz LM; Hall RC; Scheidt JH; Sun D; Sun Z; Gopalakrishnan R; Lu ZR
Pharm Res; 2021 Aug; 38(8):1405-1418. PubMed ID: 34389916
[TBL] [Abstract][Full Text] [Related]
4. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin.
Vaidya A; Ayat N; Buford M; Wang H; Shankardass A; Zhao Y; Gilmore H; Wang Z; Lu ZR
Theranostics; 2020; 10(24):11127-11143. PubMed ID: 33042274
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer.
Hall RC; Ayat NR; Qiao PL; Vaidya AM; Ma D; Aminoshariae A; Stojanov I; Lu ZR
Mol Imaging Biol; 2020 Dec; 22(6):1532-1542. PubMed ID: 32789648
[TBL] [Abstract][Full Text] [Related]
7. Effective MR Molecular Imaging of Triple Negative Breast Cancer With an EDB-Fibronectin-Specific Contrast Agent at Reduced Doses.
Ayat NR; Vaidya A; Yeung GA; Buford MN; Hall RC; Qiao PL; Yu X; Lu ZR
Front Oncol; 2019; 9():1351. PubMed ID: 31850230
[TBL] [Abstract][Full Text] [Related]
8. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.
Lu ZR; Laney V; Li Y
Acc Chem Res; 2022 Oct; 55(19):2833-2847. PubMed ID: 36121350
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis.
Qiao PL; Gargesha M; Liu Y; Laney VEA; Hall RC; Vaidya AM; Gilmore H; Gawelek K; Scott BB; Roy D; Wilson DL; Lu ZR
Magn Reson Imaging; 2022 Feb; 86():37-45. PubMed ID: 34801672
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts.
Qiao P; Ayat NR; Vaidya A; Gao S; Sun W; Chou S; Han Z; Gilmore H; Winter JM; Lu ZR
Front Oncol; 2020; 10():586727. PubMed ID: 33194740
[TBL] [Abstract][Full Text] [Related]
11. Regulating Oncogenic LncRNA DANCR with Targeted ECO/siRNA Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Nicolescu C; Vaidya A; Schilb A; Lu ZR
ACS Omega; 2022 Jul; 7(26):22743-22753. PubMed ID: 35811871
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells.
Vaidya A; Wang H; Qian V; Gilmore H; Lu ZR
Cells; 2020 Aug; 9(8):. PubMed ID: 32756405
[TBL] [Abstract][Full Text] [Related]
13. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.
Han Z; Cheng H; Parvani JG; Zhou Z; Lu ZR
Magn Reson Med; 2018 Jun; 79(6):3135-3143. PubMed ID: 29082597
[TBL] [Abstract][Full Text] [Related]
15. MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles.
Sun Y; Kim HS; Park J; Li M; Tian L; Choi Y; Choi BI; Jon S; Moon WK
Theranostics; 2014; 4(8):845-57. PubMed ID: 24955145
[TBL] [Abstract][Full Text] [Related]
16. LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression.
Tao W; Wang C; Zhu B; Zhang G; Pang D
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910842
[TBL] [Abstract][Full Text] [Related]
17. EDB Fibronectin-Specific SPECT Probe
Ye XX; Zhao YY; Wang Q; Xiao W; Zhao J; Peng YJ; Cao DH; Lin WJ; Si-Tu MY; Li MZ; Zhang X; Zhang WG; Xia YF; Yang X; Feng GK; Zeng MS
ACS Omega; 2017 Jun; 2(6):2459-2468. PubMed ID: 30023665
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.
Li Y; Han Z; Roelle S; DeSanto A; Sabatelle R; Schur R; Lu ZR
Mol Pharm; 2017 Nov; 14(11):3906-3915. PubMed ID: 28976766
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery.
Yu M; Ortega CA; Si K; Molinaro R; Schoen FJ; Leitao RFC; Xu X; Mahmoudi M; Ahn S; Liu J; Saw PE; Lee IH; Brayner MMB; Lotfi A; Shi J; Libby P; Jon S; Farokhzad OC
Theranostics; 2018; 8(21):6008-6024. PubMed ID: 30613278
[TBL] [Abstract][Full Text] [Related]
20. Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma.
Saw PE; Xu X; Kang BR; Lee J; Lee YS; Kim C; Kim H; Kang SH; Na YJ; Moon HJ; Kim JH; Park YK; Yoon W; Kim JH; Kwon TH; Choi C; Jon S; Chong K
Theranostics; 2021; 11(2):941-957. PubMed ID: 33391514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
